Article Details
Retrieved on: 2024-12-01 14:21:40
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a study by the Schepens Eye Research Institute exploring mRNA-based therapy, focusing on RUNX1 to treat retinal diseases like proliferative vitreoretinopathy and macular degeneration. This showcases biopharma's potential in ocular gene expression applications.
Article found on: www.modernretina.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here